Get started

Insiderbuying

PLAY | Excellent Long Term Play | LONGDave & Buster's Entertainment, Inc. owns and operates entertainment and dining venues for adults and families in North America. Its venues offer a menu of entrees and appetizers, as well as a selection of non-alcoholic and alcoholic beverages; and an assortment of entertainment attractions centered on playing games and watching live sports, and other televised events. The company operates its venues under the Dave & Buster's name. As of January 30, 2022, it owned and operated 144 stores located in 40 states, Puerto Rico, and one Canadian Province. The company was founded in 1982 and is headquartered in Coppell, Texas.
NASDAQ:PLAYLong
by DivergenceSeeker
2
ET Insider Buy Signal & Technical BullishAnother interesting signal from the oil sector was generated yesterday by our directorscope AI system. With a risk / reward ratio of 5.3 over the medium term, this could be a good trade. Elliott Wave Analysis: The stock could be inside a wave 3. And within the wave in an intermediate correction. With current impulses from the oil price, the interim correction could now be over. RSI shows at this points divergence behavior, which is bullish in short term as well. Stochastic indicator shows neutral levels. We set a small position (0.5% of the portfolio value) with a very tight stop. Keep in mind, this stock is highly depending on oil prices.
NYSE:ETLong
by director_scope
$LUMN - Lumen Technologies - Insider Buying & Resistance Break3/3/21 $LUMN - Lumen Technologies - 7.315% Gainer Catalysts: 5 Form 4's filed after hours on March 2nd. Confirming some heavy insider buying in late February. This combined with the stock price in a bullish uptrend and at resistance caused a breakout. -I'm going to be taking a look at some of the top daily gainers (may throw in some losers occasionally) of the day on their daily charts and posting them here throughout March. This is not advice. Just analyzing price action and patterns. -I will try to vary the catalysts (analyst upgrades, earnings, clinical trial results, etc.) for the stock moving (if any) and the sector that the stocks are in. -You'll notice I try to keep my charts as simple as possible. Black background and no grid. I will be focusing solely on price action, patterns, and support and resistance levels. No moving averages, MACD, volume profiles, Bollinger bands, etc. Please feel free to comment or leave suggestions. I am always looking to improve. Thanks.
NYSE:LUMN
by mgallagher1
Insider confidence in Adial Pharmaceuticals bodes wellAs Adial Pharmaceuticals advances its Phase 3 clinical trial of AD04 for the treatment of alcohol use, insiders are showing confidence in the company. Today they appointed Mark Howard Peikin as chief strategy officer, and he took the position without a salary. Instead, he accepted a stock option as his sole compensation plan. Chief medical officer Johnson A. Bankole also just acquired over 3,000 shares, perhaps as part of his own compensation plan. If AD04 succeeds in clinical trials, it could be a very profitable drug.
NASDAQ:ADILLong
by ChristopherCarrollSmith
Buy targets on MUUpon dropping to 42 and approaching oversold territory, Micron has gotten some positive catalysts. A couple analyst agencies have upgraded Micron, bringing its Equity StarMine Summary Score to a surprising 8.9/10. Also, yesterday Micron filed a Form 4 indicating that one of the directors had purchased some shares. Unlikely though it seems to me given Micron's poor earnings right now, the stock may get a short-term bounce from 40 or so. I suspect, though, that there will be opportunities to buy at a cheaper price later in October. I'd like to see 32.50 or even 28 before I'd buy. Just as a side note, I was shocked by the name on that Form 4. Patrick Byrne is a director of Micron?? This is the guy who recently got forced out as CEO of Overstock.com after his girlfriend got convicted as a Russian spy. Dude's a total loon, and I find this a little worrying for Micron.
NASDAQ:MU
by ChristopherCarrollSmith